rs261532

This variant is located in the UBE2D2 gene.

Research that mentions this SNP (1)

Genome-wide analysis of polymorphisms associated with cytokine responses in smallpox vaccine recipients
AssociationN=1,000Kennedy RB et al.(2012)· Human Genetics

Genome-wide association study identifying SNPs associated with cytokine responses to vaccinia virus in 1,000 smallpox vaccine recipients. Multiple SNPs achieved genome-wide significance (p<5×10⁻⁷) for Th1 cytokines (IL-2, TNFα, IL-12p40) and inflammatory cytokines (IL-1β, IFNα, IL-6). Notable findings include rs16948200 in NGFR (12-fold difference in IL-2 secretion between genotypes), rs4251424 in IRAK4 (associated with TNFα), and rs2255327 in BLK (2-fold higher IL-6 in heterozygotes).

Traits studied:Cytokine response to vaccinia virusIFN alpha secretionIFN beta secretionIL-1 beta secretionIL-10 secretionIL-12p40 secretionIL-12p70 secretionIL-18 secretionIL-2 secretionIL-4 secretionIL-6 secretionInflammatory responseTNF alpha secretionTh1 immune responseTh2 immune response

About UBE2D2

Regulated degradation of misfolded, damaged or short-lived proteins in eukaryotes occurs via the ubiquitin (Ub)-proteasome system (UPS). An integral part of the UPS system is the ubiquitination of target proteins and covalent linkage of Ub-containing proteins to form polymeric chains, marking them as targets for 26S proteasome-mediated degradation. Ubiquitination of proteins is mediated by a cascade of enzymes which includes E1 (ubiquitin activating), E2 (ubiquitin conjugating), and E3 (ubiquitin ligases) enzymes. This gene encodes a member of the E2 enzyme family. Substrates of this enzyme include the tumor suppressor protein p53 and peroxisomal biogenesis factor 5 (PEX5). Alternative splicing results in multiple transcript variants of this gene. [provided by RefSeq, May 2013]

View all UBE2D2 variants →

Gene information from NCBI Gene. Variant classifications from ClinVar.

Community Wiki

No community notes yet for this variant. Sign in to start one.

Comments

Sign in to join the discussion.

Loading comments…